TG Therapeutics, Inc. is a biopharmaceutical company that focuses on developing treatments for B-cell malignancies and autoimmune diseases. The company's product candidates include Ublituximab and Umbralisib, which are monoclonal antibodies for the treatment of various cancers. It also has other preclinical and collaborative programs with various organizations to develop new therapeutic options.